Rupee jumps 32 paise to 75.30 in early trade; govt's reopening plan for domestic economy boosts investors sentiment

The rupee appreciated 32 paise to 75.30 against the US dollar in opening trade on Monday supported by the government's reopening plan for the domestic economy

Press Trust of India June 01, 2020 11:17:11 IST
Rupee jumps 32 paise to 75.30 in early trade; govt's reopening plan for domestic economy boosts investors sentiment

Mumbai: The rupee appreciated 32 paise to 75.30 against the US dollar in opening trade on Monday supported by the government's reopening plan for the domestic economy.

Forex traders said foreign fund inflows, weak American currency and positive opening of domestic equities also boosted investor confidence.

The rupee opened at 75.32 at the interbank forex market and then gained further ground to touch 75.30, up 32 paise over its last close.

It had settled at 75.62 against the US dollar on Friday.

The government on Saturday said a phased exit would begin on June 1 from the over-two-months-long nationwide lockdown.

Announcing the new guidelines, the home ministry said a complete lockdown would continue till June 30 in areas identified as COVID-19 containment zones across the country, but restrictions would be lifted in a phased manner at other places after the ongoing fourth phase.

Reliance Securities in a report said Asian currencies have more or less started with gains against the US gollar supported by less severe response from US President Donald Trump.

Click here to follow LIVE news and updates on stock markets

Meanwhile, in India, the death toll due to COVID-19 rose to 5,394 and the number of cases surged past 1.90 lakh, according to the health ministry.

The number of cases around the world linked to the disease has crossed over 61.66 lakh and the death toll has topped 3.72 lakh.

Click here to follow LIVE updates on coronavirus outbreak

On the equities front, the 30-share BSE benchmark Sensex was quoting 865.44 points higher at 33,289.54 and broader Nifty rose 244.10 points to 9,824.40.

Foreign institutional investors were net buyers in the capital market, as they bought equity shares worth Rs 1,460.71 crore on Friday, according to provisional exchange data.

Brent crude futures, the global oil benchmark, fell 0.63 percent to $37.60 per barrel.

The dollar index, which gauges the greenback's strength against a basket of six currencies, fell by 0.33 percent to 98.02.

Meanwhile, India's GDP growth tumbled to 3.1 percent in the March quarter -- the slowest pace since the global financial crisis more than a decade back. In 2019-20, the Indian economy grew by 4.2 percent, the slowest in 11 years.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Andy Murray backs compulsory vaccine programme for tennis tournaments
Sports

Andy Murray backs compulsory vaccine programme for tennis tournaments

With the 2021 tennis schedule facing inevitable issues with the Covid-19 pandemic, three-time Grand Slam winner Murray hopes the long-awaited vaccine will be available by the spring and that a compulsory programme is rolled out within tennis.

Social bubbles, physical distancing, masks: Which method is most effective in controlling COVID-19 spread at events
Health

Social bubbles, physical distancing, masks: Which method is most effective in controlling COVID-19 spread at events

A new study published in the Proceedings of the National Academy of Sciences (PNAS) has conducted precisely this type of evaluation of various social settings which can lead to COVID-19 outbreaks to understand which preventive methods are best suited for which type of situation

Pfizer says its COVID-19 vaccine safe and 95% effective; to seek emergency use approval 'in days'
World

Pfizer says its COVID-19 vaccine safe and 95% effective; to seek emergency use approval 'in days'

The company didn’t disclose safety details but said no serious side effects have been reported, with the most common problem being fatigue after the second vaccine dose, affecting about four percent of participants